Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000466909 | SCV000544539 | benign | Tuberous sclerosis 2 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001023422 | SCV001185292 | likely benign | Hereditary cancer-predisposing syndrome | 2020-10-29 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001538711 | SCV001756395 | likely benign | not provided | 2019-08-01 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV001538711 | SCV002011326 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000466909 | SCV002040243 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV001023422 | SCV002534001 | likely benign | Hereditary cancer-predisposing syndrome | 2021-04-20 | criteria provided, single submitter | curation | |
Ce |
RCV001538711 | SCV004129876 | uncertain significance | not provided | 2022-04-01 | criteria provided, single submitter | clinical testing |